PT-141 for Libido: What the Evidence Shows
What human and animal studies show about PT-141 for libido, how strong that evidence is, and what is still unproven.
- Strongest evidence
- Human RCT
- Human studies
- 8
- PubMed records, our ledger
- Animal studies
- 1
- PubMed records, our ledger
- Studies we summarised
- 9
- with an outcome for libido
Evidence for libido
Each row is an outcome related to libido from a published study, strongest design first. Animal and cell results are labelled and are not human results. User reports are not counted as evidence here.
| Outcome | Result | Study type | Source |
|---|---|---|---|
| Desire and distress across subgroups | Benefit on desire and distress was seen across age, weight and BMI subgroups. | Human RCTn = 1202 | Journal of women's health 2022, PMID 35230162 |
| Patient-reported experience | Exit surveys and interviews: bremelanotide users described more desire, arousal and better sexual activity quality. | Human RCTn = 242 | Journal of women's health 2021, PMID 33538638 |
| Sexual desire (FSFI-desire domain) | Desire domain score rose more than placebo: 0.30 (study 301), 0.42 (study 302), 0.35 integrated, all P<.001. | Human RCTn = 1267 | Obstetrics and gynecology 2019, PMID 31599840 |
| Distress related to low desire | Distress fell more than placebo: -0.37, -0.29 and -0.33 integrated. | Human RCTn = 1267 | Obstetrics and gynecology 2019, PMID 31599840 |
| Responder rates | At 1.75 mg, responder rates beat placebo on all 7 endpoints (P ≤ .03). | Human RCT | The journal of sexual medicine 2019, PMID 31277966 |
| Satisfying sexual events | +0.7 versus +0.2 satisfying sexual events per month (p = 0.0180). | Human RCTn = 327 | Women's health 2016, PMID 27181790 |
| Positive clinical response in sildenafil non-responders | 51 (33.5%) of the bremelanotide group had positive clinical results versus 13 (8.5%) on placebo (p = 0.03). | Human RCTn = 342 | The Journal of urology 2008, PMID 18206919 |
| Sexual desire | More women reported moderate or high desire after bremelanotide than placebo (P = 0.0114). | Human RCTn = 18 | The journal of sexual medicine 2006, PMID 16839319 |
| Vaginal vasocongestion | No significant change in vaginal vasocongestion versus placebo. | Human RCTn = 18 | The journal of sexual medicine 2006, PMID 16839319 |
| Erectile response (RigiScan) | Erectile response was statistically significant versus placebo at both 4 mg and 6 mg in men with inadequate response to Viagra. | Human RCT | International journal of impotence research 2004, PMID 14999221 |
| Erectile response (RigiScan) | Erectile response beat placebo at doses above 7 mg; first erection began in about 30 minutes. | Human RCT | International journal of impotence research 2004, PMID 14963471 |
PubMed records for PT-141 and libido: 8 human, 1 animal (search counts, not studies we reviewed). Grades follow our .
How strong is it?
A human randomized trial outweighs any number of animal studies. Animal and cell results show a mechanism worth testing, not that it works in people.
Erectile dysfunction versus low desire
MedlinePlus defines erectile dysfunction as a man having trouble getting or keeping an erection.[10]
It lists lack of sexual desire, inability to become aroused, lack of orgasm and painful intercourse as the problems that can keep a woman from enjoying sex.[11]
What the FDA-approved version is and is not for
Vyleesi, the approved bremelanotide product, is indicated for premenopausal women with acquired, generalized hypoactive sexual desire disorder.[12]
Its label says it is not indicated for HSDD in postmenopausal women or in men, and not to enhance sexual performance.[12]
The erectile dysfunction trials that were run
A randomized trial in men whose sildenafil had failed gave intranasal bremelanotide, with positive clinical results in 33.5% against 8.5% on placebo.[6]
That trial also reported more drug-related adverse effects on bremelanotide.[6]
In a crossover trial in men with ED, an erectile response to PT-141 4 mg or 6 mg was statistically significant versus placebo.[8]
A separate PT-141 study reported a statistically significant erectile response versus placebo at doses greater than 7 mg, with the first erection starting in approximately 30 min.[9]
Desire trials in women
In studies 301 and 302, women taking bremelanotide had statistically significant increases in sexual desire scores compared with placebo.[3]
Label safety information
The label reports nausea in 40% of patients who received up to 8 monthly doses, with 8% stopping early.[12]
The label contraindicates it in patients with uncontrolled hypertension or known cardiovascular disease.[12]
The label advises patients to discontinue it if pregnancy is suspected.[12]
Other peptides people research for libido
Common questions
Does PT-141 help with libido?
The strongest study we summarise for libido is human rct evidence, across 9 studies with an outcome for libido. A trial result is not an approval; see the legal status.
Is PT-141 approved for libido?
PT-141 is FDA approved for HSDD (Vyleesi). Which conditions that approval covers is set by the label; use for anything else is off-label.
Does PT-141 work for erectile dysfunction?
In men whose sildenafil had failed, intranasal bremelanotide gave positive clinical results in 33.5% against 8.5% on placebo; that is a trial result, not an approved use.[6]
Is PT-141 FDA approved for libido?
The approved form is Vyleesi, for premenopausal women with HSDD. Its label says it is not indicated in men or to enhance sexual performance.[12]
What are the side effects of PT-141?
In the label's data nausea was reported by 40% of patients, requiring anti-emetic therapy in 13%.[12]
More on PT-141
Sources
- 1Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide.Journal of women's health (2002) · 2022PMID 35230162Accessed 2 Oct 2026
- 2The Patient Experience of Premenopausal Women Treated with Bremelanotide for Hypoactive Sexual Desire Disorder: RECONNECT Exit Study Results.Journal of women's health (2002) · 2021PMID 33538638Accessed 2 Oct 2026
- 3Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials.Obstetrics and gynecology · 2019PMID 31599840Accessed 2 Oct 2026
- 4Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide.The journal of sexual medicine · 2019PMID 31277966Accessed 2 Oct 2026
- 5Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial.Women's health (London, England) · 2016PMID 27181790Accessed 2 Oct 2026
- 6Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study.The Journal of urology · 2008PMID 18206919Accessed 2 Oct 2026
- 7An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist.The journal of sexual medicine · 2006PMID 16839319Accessed 2 Oct 2026
- 8Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra.International journal of impotence research · 2004PMID 14999221Accessed 2 Oct 2026
- 9Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction.International journal of impotence research · 2004PMID 14963471Accessed 2 Oct 2026
- 10Official web pageOfficial web page · web page
- 11medlineplus.gov pagemedlineplus.gov · web pagemedlineplus.gov
- 12VYLEESI prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
Found an error? Report a correction.